Multidisciplinary lifestyle interventions for neurological disorders during the Silent phase (MINDS) study: a
Sara Taylor1, Seerat Sachdeva2, Sandra Darling3,4
1Epilepsy Center, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA.
Neurological Research and Practice
|July 31, 2024
Summary
This study investigates if multidisciplinary lifestyle interventions (MLI) can slow neurological disorder progression in at-risk older adults. It also seeks to identify biomarkers for early detection and to measure MLI effectiveness.
Area of Science:
- Neurology
- Preventive Medicine
- Biomarker Discovery
Background:
- Neurological disorders pose significant health and economic burdens.
- Early detection and intervention are crucial for managing neurological conditions.
- Multidisciplinary lifestyle interventions (MLI) show promise in mitigating neurological disorder risk.
Purpose of the Study:
- To evaluate the impact of MLI on the progression of neurological disorders.
- To identify multi-omic biomarkers for early-stage neurological diseases.
- To assess MLI's effect on these identified biomarkers.
Main Methods:
- The Multidisciplinary lifestyle Interventions for Neurological Disorders during the Silent phase (MINDS) protocol is a randomized controlled trial.
- Participants (≥50 years) at elevated risk for stroke, epilepsy, Parkinson's, or Alzheimer's are randomized to intervention or control groups.
- The intervention includes diet, yoga, music therapy, and cognitive training over 3 months, with 12-month follow-up including neuroimaging and multi-omic analyses.
Main Results:
- Primary outcomes focus on neurological disorder risk progression or clinical diagnosis.
- Secondary outcomes include self-reported health and multi-omic data.
- Data analysis will compare between-group and within-group longitudinal changes.
Conclusions:
- The MINDS trial will clarify MLI's efficacy in older adults at risk for neurological disorders.
- Biomarker data will validate MLI's impact on disease progression.
- This research aims to identify individuals who may benefit most from early MLI therapies.


